07/04/2025
Dear Valued Patient,
We're writing to inform you about recent developments regarding tirzepatide (marketed as Zepbound and Mounjaro) and its availability through compounding pharmacies.
Eli Lilly, the manufacturer of Zepbound and Mounjaro, has initiated legal action against Strive Pharmacy regarding compound production. While Strive anticipated this development, they chose to continue providing compounded versions of the medication, recognizing its significant positive impact on patients' health journeys.
Current Status: Strive Pharmacy remains operational and continues to provide services. However, new prescription protocols likely will be implemented:
1. Patients without specific clinical requirements will be directed to brand-name/commercial versions of the medication (Zepbound or Mounjaro)
2. Patients requiring the compounded version must have documented clinical justification. Without proper documentation, prescriptions will not be processed. We will try to provide this documentation to all who need it.
Strive has released an official statement:
“This isn’t just an attack on Strive Pharmacy, this is an attack on personalized medicine, patient access, patient choice, and healthcare provider discretion. This is a classic example of Big Pharma overstepping legitimate regulations and prioritizing their own interests over patients’ and the general public is catching on. If Strive Pharmacy is the only one holding the line, so be it. Our patients and providers deserve our effort. Strive will vigorously defend our position and we look forward to being vindicated in the courts.”
We are fighting for more than ourselves. Strive is all about the people. We exist to enable fuller, healthier lives for people. We proudly represent the “personal side of healthcare.”
We understand these changes may affect your treatment plan. Our team is committed to working with you to ensure continuous access to appropriate medication options that best serve your health needs.
Please contact our office if you have questions about how these changes might affect your prescription or if you need to discuss alternative treatment options.
Thank you for your understanding as we navigate these regulatory changes together. For any questions or concerns, please contact our business line directly at 623-755-5123. This line is actively monitored and all calls and texts will be answered. This is the preferred method of communication. Responses via Facebook messenger or my cell phone may be delayed as I am typically in clinic.
Warm Regards,
Jeffrey Roth, NP
Nurse Practitioner
